Insmed Shares Jump 18% After Arikayce Late-Stage Win Insmed (INSM) rallied ~18% on Mar 23, 2026 after a late-stage Arikayce trial reportedly met its primary endpoint; full data and regulatory plans are pending (Seeking Alpha, Mar 23, 2026).

Insmed Shares Jump 18% After Arikayce Late-Stage Win: Insmed (INSM) rallied ~18% on Mar 23, 2026 after a late-stage Arikayce trial reportedly met its primary endpoint; full data and regulatory plans are pending… 👈 Read full analysis #Insmed #Arikayce #Pharmaceuticals #ClinicalTrials #Biotech

Insmed's 2025 Financial Results Show Robust Growth and Future Prospects for BRINSUPRI Insmed has reported strong financial results for 2025, highlighting significant growth in revenues from BRINSUPRI and ARIKAYCE. The company anticipates continued expansion in 2026.

Insmed's 2025 Financial Results Show Robust Growth and Future Prospects for BRINSUPRI #United_States #Bridgewater #Insmed #ARIKAYCE #Brinsupri

Insmed Releases Business Update and Future Outlook at J.P. Morgan Healthcare Conference Insmed presented significant revenue growth and future plans for their drug portfolio during the J.P. Morgan Healthcare Conference.

Insmed Releases Business Update and Future Outlook at J.P. Morgan Healthcare Conference #United_States #San_Francisco #Insmed #ARIKAYCE #Brinsupri

Insmed Reports Impressive Third-Quarter 2025 Financial Results and Updates on Product Launches Insmed Incorporated shares its third-quarter 2025 financial results, highlighting significant progress in treatment approvals and revenue growth for its products.

Insmed Reports Impressive Third-Quarter 2025 Financial Results and Updates on Product Launches #United_States #Insmed #ARIKAYCE #Bridgewater,_NJ #Brinsupri

Insmed Announces Strong Second-Quarter 2025 Revenue Growth and Updates Clinical Trajectory Insmed's second-quarter 2025 results show a 19% growth in revenue driven by ARIKAYCE, with exciting clinical updates on brensocatib and other therapies.

Insmed Announces Strong Second-Quarter 2025 Revenue Growth and Updates Clinical Trajectory #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Insmed Announces $750 Million Public Stock Offering to Enhance Biopharmaceutical Development Insmed has priced a $750 million public offering of common stock to support its biopharmaceutical innovations and expansion. This funding aims to drive advanced research and commercialization efforts.

Insmed Announces $750 Million Public Stock Offering to Enhance Biopharmaceutical Development #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Significant Growth Expected in MAC Lung Disease Market by 2034: Innovations and Rising Cases Drive Change The MAC lung disease market is set to experience substantial growth through 2034, fueled by innovative therapies and increasing prevalence. New drugs are emerging to address this condition.

Significant Growth Expected in MAC Lung Disease Market by 2034: Innovations and Rising Cases Drive Change #United_States #Las_Vegas #ARIKAYCE #MAC_Lung_Disease #MNKD-101

Insmed's First-Quarter 2025 Recap: Growth and Anticipated Milestones Ahead Insmed Incorporated has reported its financial results for Q1 2025, showcasing significant revenue growth and outlining milestones for upcoming drug approvals and studies.

Insmed's First-Quarter 2025 Recap: Growth and Anticipated Milestones Ahead #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Insmed's Impressive 2024 Financial Performance and Growth Outlook Insmed Incorporated reports strong revenues for 2024 and anticipates continued growth driven by ARIKAYCE® and upcoming product launches. Discover the company's strategic updates.

Insmed's Impressive 2024 Financial Performance and Growth Outlook #USA #Bridgewater,_New_Jersey #Insmed #ARIKAYCE #brensocatib

Insmed's Business Update Highlights Promises for 2025 Growth at J.P. Morgan Conference Insmed Incorporated announced impressive revenue forecasts and upcoming product launches at the 43rd J.P. Morgan Healthcare Conference, highlighting a strong business outlook.

Insmed's Business Update Highlights Promises for 2025 Growth at J.P. Morgan Conference #USA #San_Francisco #Insmed #ARIKAYCE #brensocatib